SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
SEC Accession No. 0001193125-19-052893
Filing Date
2019-02-27
Accepted
2019-02-27 07:58:57
Documents
7
Effectiveness Date
2019-02-27

Document Format Files

Seq Description Document Type Size
1 POSASR d677961dposasr.htm POSASR 534849
2 EX-1.2 d677961dex12.htm EX-1.2 189234
3 EX-4.4 d677961dex44.htm EX-4.4 253948
4 EX-4.5 d677961dex45.htm EX-4.5 263206
5 EX-5.1 d677961dex51.htm EX-5.1 13149
6 EX-23.1 d677961dex231.htm EX-23.1 1934
7 GRAPHIC g677961g57j37.jpg GRAPHIC 33539
  Complete submission text file 0001193125-19-052893.txt   1303568
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: POSASR | Act: 33 | File No.: 333-227814 | Film No.: 19635843
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences